8:25 am Chair’s Opening Remarks

  • Puja Sapra Vice President, Head of Tumor Targeted Delivery, Oncology R&D , AstraZeneca

8:30 am Preclinical Profile of SYD1875, a Novel Site- Specifically Conjugated Anti- 5T4 Antibody Drug Conjugate

  • Patrick Groothuis Principal Scientist - In Vivo Pharmacology, Toxicology, Drug Metabolism & Pharmacokinetics , Byondis


• SYD1875 comprises a humanized, HC41-cysteine-engineered IgG1 monoclonal antibody that targets 5T4
• SYD1875 is site-specifically conjugated to a proprietary cleavable synthetic duocarmycin-based linker-drug (vc-seco-
DUBA), which yields a homogeneous and stable ADC with favorable physicochemical properties and manufacturability
• SYD1875 is a potent ADCnwith anti-tumor activity in multiple solid tumor types with high, moderate and low 5T4
expression levels. Its preclinical profile supports the expectation that SYD1875 will be of benefit for a broad group of cancer
patients. A first-in-human dose-finding trial is initiated to evaluate safety and explore efficacy (NCT04202705).

9:00 am ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform

  • Zhala Tawfiq Process Development & TT Associate Scientist, Ajinomoto Bio- Pharma Services


  • Review how site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies
  • Reporting a novel method of affinity peptide mediated regiodivergent antibody functionalization that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner
  • Presenting how both thiol-based and azide-based site-specific ADCs produced by “AJICAP” technology demonstrated an expansion of their therapeutic index compared with stochastic technology

9:30 am Providing an Update on the Development of Patritumab Deruxtecan (HER3-DXd; U3-1402) A HER3- Directed DXd Antibody-Drug Conjugate (ADC)

  • Gilles Gallant Senior Vice President, Global Head of Oncology Development, Oncology R&D, Daiichi Sankyo


  • Assess the mechanism of action and preclinical profile of HER3-DXd
  • Examine the clinical development of HER3-DXd in non-small cell lung cancer (NSCLC)
  • Discuss the future development of HER3-DXd

10:00 am Exploring the Future of Seagen’s ADC Leadership: Insights from Phase I ADC Pipeline with First- &/or Best-In- Class Potential


  • Overview of novel targeted therapies in Seagen’s ADC early pipeline
  • Highlights from preclinical data for clinical stage Ph 1 ADC portfolio
  • Outlining Ph 1 trial designs enabling accelerated insight and decision-making

10:30 am Morning Refreshments & Virtual Speed Networking


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

1:00 pm Lunch & Networking

Delving into Alternative Format ADCs

2:00 pm Re-Imagining ADCs & Looking at Novel Format – Synthetic Immuno-lethality

  • Neil Bander Professor, Bernard and Josephine Chaus Chair in Urological Oncology, & Director of Urological Oncology Research , Weill Cornell Medicine


  • Replace drug/toxin with native enzyme
  • Revise tumor immuno-phenotype
  • Explore synthetic immuno-lethality

2:30 pm Immunomodulatory Antibody Conjugates for the Treatment of Cancer & Chronic Viral Infections

  • Valerie Odegard President & Chief Scientific Officer, Silverback Therapeutics


  • An overview of Silverback’s ImmunoTAC (Immunomodulatory Targeted Antibody Conjugate) technology platform
  • Discussing the discovery and development of ImmunoTAC molecules containing a TLR8 agonist payload designed to stimulate local activation of myeloid cells
  • Examining how broad and versatile potential of the ImmunoTAC platform is exemplified by oncology (SBT6050 and SBT6290) and virology (SBT8230) development candidates

3:00 pm Radioactive ADCs in Oncology & Autoimmune Diseases


• Radioimmunoconjugates are not a new class of drugs but improvements in conjugation technology, choices of isotopes
and antibody engineering techniques has generated new interest
• Highlighting significant opportunities in both diagnostic and therapeutic medicine
• Outlining a number of recent late-stage developments in this exciting field, as well as potentially important new platform
technologies for the future

3:30 pm Afternoon Refreshments & Networking Scientific Poster Session

Exploring Key Clinical Updates from Promising Candidates

4:30 pm Delving into XMT-1660, XMT-1592 & the Dolasynthen Platform


  • Outlining how the Dolasynthen platform is a fully homogeneous, defined platform compatible with multiple site specific bioconjugation technologies
  • Highlighting the opportunity Dolasynthen provides to precisely create ADCs with DARs ranging from 2 to 18+ with full homogeneity
  • Providing details on the Dolasynthen ADCs XMT-1660 targeting B7H4 and XMT-1592, targeting NaPi2b

5:00 pm ROR1 Targeting with the Antibody Drug-Conjugate MK-2140 in Aggressive Non-Hodgkins Lymphoma

  • Douglas A Levine Senior Principal Scientist, Early Oncology Development , Merck Research Labs


  • Discussing how Receptor tyrosine kinase-like orphan receptor 1 (ROR1) represents an attractive, cancer-specific, cellsurface target for antibody-based therapies
  • MK-2140 is a novel antibody-drug conjugate (ADC) that binds to an external ROR1 epitope and rapidly internalizes to deliver monomethyl auristatin E (MMAE) to tumor cells
  • Evaluating how this Phase 1 dose-ranging study provides the first clinical proof of concept for targeting ROR1, demonstrating a predictable safety profile and durable objective tumor responses in patients with advanced lymphoma

5:30 pm A Kadcyla Patient’s Experience: Hope & Healing


  • One in eight
  • Fight for life
  • Better than before

5:45 pm Chair’s Closing Remarks

  • Puja Sapra Vice President, Head of Tumor Targeted Delivery, Oncology R&D , AstraZeneca